Published: February 2024

Last updated: February 2024

The Public Health Impact of Introducing an mRNA-Based Respiratory Syncytial Virus (RSV) Vaccine Among Adults = 65 Years in The UK

BACKGROUND: RSV is an important cause of lower respiratory tract disease (LRTD) in older adults and may cause substantial morbidity, mortality, and economic disruption. The Joint Committee on Vaccination and Immunisation (JCVI) advised introducing a one-off RSV vaccine into the national immunisation schedule for adults aged 75-80. The potential impact of mRNA-1345, an RSV vaccine, was explored for UK adults aged =65, aligned with current influenza vaccine recommendations.

METHODS: A decision-analytic model (Figure 1) was developed to estimate the clinical impact of mRNA-1345 compared with no vaccine over two-years from a UK perspective. Trial data (Wilson et al 2023) was used to populate mRNA-1345 efficacy in preventing RSV-LRTD, RSV-acute respiratory disease (ARD), and RSV-hospitalizations, projected over two-years. Table 1 shows the key inputs. Outcomes included RSV-case numbers, RSV-LRTD hospitalisations, numbers needed to vaccinate (NNV) to prevent these outcomes, incremental life years and quality-adjusted life-years (QALYs).

RESULTS: When targeting UK adults aged =65, compared to no vaccination, administering mRNA-1345 could result in a 33.8%, 38.6%, and 52.0% reduction in cases of RSV-ARD, RSV-LRTD, and deaths respectively. A reduction of 29,412 RSV-LRTD hospitalisations (52.0%) were estimated. Vaccination was estimated to save 95,556 QALYs and 121,885 life-years over two-years for a total population of 12,537,031. The NNV to prevent one RSV-LRTD case, one RSV hospitalisation and one death was 57, 426 and 755, respectively.

CONCLUSIONS: In UK adults aged =65, implementing mRNA-1345 could have a significant impact on reducing RSV-related morbidity and mortality, and as a result reduce healthcare resource use and improve population quality of life.

You may also be interested in

Peer-reviewed publication

The Economic and Clinical Impact of an AI-Assisted Tool for Colonoscopy to Support Diagnosis of Colorectal Cancer in Symptomatic Patients in England

YHEC authors: Luc Curtis-Gretton, Angel Varghese, Karina Watts, Hayden Holmes
Publication date: November 2026
Publishers: Springer Nature Link
Journal: BMC Digital Health

Abstract

BACKGROUND: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality in the UK. Early detection and removal of adenomatous polyps are essential to improving outcomes. Artificial intelligence-assisted colonoscopy tools,...

Peer-reviewed publication

Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Asymptomatic Severe Aortic Stenosis in the Kingdom of Saudi Arabia

YHEC authors: Madison Montgomery, Heather Davies, Lucy Hillcoat
Publication date: October 2026
Journal: Frontiers in Cardiovascular Medicine

Abstract

INTRODUCTION: Aortic stenosis (AS) is defined as the narrowing of the aortic valve. The benefits of implementing early aortic valve replacement (AVR), while the AS is asymptomatic, have been demonstrated...

Peer-reviewed publication

What is the Role of Multidisciplinary Methods to Support Environmental Sustainability in Health Technology Assessment?

YHEC authors: Melissa Pegg, Emma Bishop, Karina Watts
Publication date: October 2026
Publishers: HTAi
Journal: International Journal of Technology Assessment in Healthcare

Abstract

Healthcare contributes up to 8.5 percent of global carbon emissions, amongst other environmental impacts including intensive water consumption, plastics in our environment and pharmaceutical associated pollution. Healthcare supply chains are...